StoxIpca Laboratories vs Ajanta Pharmaceuticals: share price & financials comparison
NSE: IPCALAB vs AJANTPHARM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ipca Laboratories vs Ajanta Pharmaceuticals at a glance
Ipca Laboratories (IPCALAB) has a market capitalisation of ₹47,797 Cr, against ₹41,165 Cr for Ajanta Pharmaceuticals (AJANTPHARM). Over the past year Ipca Laboratories has returned +45.5%, compared with +25.8% for Ajanta Pharmaceuticals. On valuation, Ajanta Pharmaceuticals trades at a lower P/E of 32.7 versus 34.1. Ajanta Pharmaceuticals earns a higher return on equity (25.9% vs 16.2%). Ipca Laboratories comes out ahead on size, momentum and technicals. Ajanta Pharmaceuticals comes out ahead on valuation, profitability, growth and financial health. Across the scored metrics below, Ipca Laboratories leads on 7 and Ajanta Pharmaceuticals on 11. On StoxGud's 10-point checklist, Ipca Laboratories scores 8/10 and Ajanta Pharmaceuticals scores 9/10.
| Metric | Ipca Laboratories | Ajanta Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹47,797 Cr | ₹41,165 Cr |
| Revenue (latest FY) | ₹9,646 Cr | ₹5,453 Cr |
| Net profit (latest FY) | ₹1,141 Cr | ₹1,056 Cr |
| Valuation | ||
| P/E | 34.1 | 32.7 |
| P/B | 5.51 | 8.47 |
| Dividend yield | 0.11% | 0.85% |
| Profitability | ||
| Return on equity | 16.2% | 25.9% |
| Net profit margin | 13.4% | 20.2% |
| Operating margin | 22.5% | 27.1% |
| Growth | ||
| Revenue growth (YoY) | +13.8% | +32.5% |
| Net profit growth (YoY) | +32.8% | +49.2% |
| Revenue CAGR (multi-year) | +12.2% | +13.5% |
| Financial health | ||
| Debt to equity | 0.07 | 0.02 |
| Momentum | ||
| 1-month return | -1.8% | -1.3% |
| 1-year return | +45.5% | +25.8% |
| 3-year CAGR | +21.3% | +20.7% |
| 5-year CAGR | +11.4% | +17.8% |
| 10-year CAGR | +21.4% | +11.2% |
| Distance from 52W high | -6.2% | -11.7% |
| Technicals | ||
| RSI (14) | 38 | 50 |
| Price vs 200-day avg | +11.2% | +2.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ipca Laboratories | Ajanta Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 8/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ipca Laboratories or Ajanta Pharmaceuticals?
Ipca Laboratories has a market cap of ₹47,797 Cr and Ajanta Pharmaceuticals has a market cap of ₹41,165 Cr as of 13 Nov 2026.
Which has a lower P/E, Ipca Laboratories or Ajanta Pharmaceuticals?
Ajanta Pharmaceuticals has the lower P/E: Ipca Laboratories trades at 34.1 and Ajanta Pharmaceuticals at 32.7.
Which gave better returns in the last year, Ipca Laboratories or Ajanta Pharmaceuticals?
Ipca Laboratories did better: Ipca Laboratories returned +45.5% and Ajanta Pharmaceuticals returned +25.8% over one year.
What is the difference between Ipca Laboratories and Ajanta Pharmaceuticals?
Both are NSE-listed companies in Healthcare. Ipca Laboratories is about 1.2 times the size of Ajanta Pharmaceuticals by market cap. In the latest financial year Ipca Laboratories reported revenue of ₹9,646 Cr and Ajanta Pharmaceuticals ₹5,453 Cr. Operating margin is 22.5% for Ipca Laboratories and 27.1% for Ajanta Pharmaceuticals. Debt to equity is 0.07 for Ipca Laboratories and 0.02 for Ajanta Pharmaceuticals.
Which is better, Ipca Laboratories or Ajanta Pharmaceuticals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Ipca Laboratories leads on 7 and Ajanta Pharmaceuticals on 11. Ipca Laboratories is ahead on size, momentum and technicals. Ajanta Pharmaceuticals is ahead on valuation, profitability, growth and financial health. On StoxGud's rules-based checklist Ipca Laboratories scores 8/10 and Ajanta Pharmaceuticals scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.